147 related articles for article (PubMed ID: 33725508)
1. Synthesis and anticancer evaluation of 6-azacyclonol-2,4,6-trimethylpyridin-3-ol derivatives: M3 muscarinic acetylcholine receptor-mediated anticancer activity of a cyclohexyl derivative in androgen-refractory prostate cancer.
Karmacharya U; Chaudhary P; Lim D; Dahal S; Awasthi BP; Park HD; Kim JA; Jeong BS
Bioorg Chem; 2021 May; 110():104805. PubMed ID: 33725508
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of BJ-1207, a 6-amino-2,4,5-trimethylpyridin-3-ol derivative, in human lung cancer.
Gautam J; Banskota S; Chaudhary P; Dahal S; Kim DG; Kang HE; Lee IH; Nam TG; Jeong BS; Kim JA
Chem Biol Interact; 2018 Oct; 294():1-8. PubMed ID: 30125546
[TBL] [Abstract][Full Text] [Related]
3. 6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.
Chaudhary CL; Lim D; Chaudhary P; Guragain D; Awasthi BP; Park HD; Kim JA; Jeong BS
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):844-856. PubMed ID: 35296193
[TBL] [Abstract][Full Text] [Related]
4. Kinase and GPCR polypharmacological approach for the identification of efficient anticancer medicines.
Park H; Jung HY; Mah S; Kim K; Hong S
Org Biomol Chem; 2020 Oct; 18(41):8402-8413. PubMed ID: 33112339
[TBL] [Abstract][Full Text] [Related]
5. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.
Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G
Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298
[TBL] [Abstract][Full Text] [Related]
6. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
8. New organoselenides (NSAIDs-Se derivatives) as potential anticancer agents: Synthesis, biological evaluation and in silico calculations.
He X; Nie Y; Zhong M; Li S; Li X; Guo Y; Liu Z; Gao Y; Ding F; Wen D; Zhang Y
Eur J Med Chem; 2021 Jun; 218():113384. PubMed ID: 33799070
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives.
Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG
Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089
[TBL] [Abstract][Full Text] [Related]
10. A concise diastereoselective approach to enantioenriched substituted piperidines and their in vitro cytotoxicity evaluation.
Kumaraswamy G; Kumar RS; Sampath B; Poornachandra Y; Ganesh Kumar C; Vemulapalli SPB; Bharatam J
Bioorg Med Chem Lett; 2014 Sep; 24(18):4439-4443. PubMed ID: 25172418
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel 1,4-benzodiazepin-3-one derivatives as potential antitumor agents against prostate cancer.
Vézina-Dawod S; Perreault M; Guay LD; Gerber N; Gobeil S; Biron E
Bioorg Med Chem; 2021 Sep; 45():116314. PubMed ID: 34333393
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents.
Shi YK; Wang B; Shi XL; Zhao YD; Yu B; Liu HM
Eur J Med Chem; 2018 Feb; 145():11-22. PubMed ID: 29310026
[TBL] [Abstract][Full Text] [Related]
14. Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft model.
Ami N; Koga K; Fushiki H; Ueno Y; Ogino Y; Ohta H
J Pharmacol Sci; 2011; 116(1):81-8. PubMed ID: 21512307
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis and Biological Evaluation of 1-methyl-1H-pyrazole-5-Carboxamide Derivatives as Novel Anti-Prostate Cancer Agents.
Chen X; Xu C; Li Y; Duan X; Zhao G
Anticancer Agents Med Chem; 2021; 21(17):2368-2378. PubMed ID: 33530916
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols.
Lee H; Banskota S; Kim DG; Been JH; Jin YJ; Gautam J; Jang H; Nam TG; Kim JA; Jeong BS
Bioorg Med Chem Lett; 2014 Jul; 24(14):3131-6. PubMed ID: 24894557
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and pharmacological evaluation of new anticancer fused pentacycles.
Chackal S; Houssin R; Pommery N; Henichart JP
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):95-9. PubMed ID: 12943192
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
